63564-50-1

Basic information

• Product Name: Propanoic acid, 3-[[[1-(4-chlorophenyl)ethylidene]amino]oxy]-, (E)-
• CAS NO: 63564-50-1
• Molecular Formula: C11H12ClNO3
• Molecular Weight: 241.674
• Mol File: 63564-50-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Propanoic acid, 3-[[[1-(4-chlorophenyl)ethylidene]amino]oxy]-, (E)-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 3-[[[1-(4-chlorophenyl)ethylidene]amino]oxy]-, (E)-(63564-50-1)
• EPA Substance Registry System: Propanoic acid, 3-[[[1-(4-chlorophenyl)ethylidene]amino]oxy]-, (E)-(63564-50-1)

Safety Data

• Hazardous Substances Data: 63564-50-1(Hazardous Substances Data)

Upstream product

• 1956-39-4 (E)-1-(4-chlorophenyl)ethanone oxime 
• 57-57-8 β-Propiolactone 
• 28191-82-4 α-methyl-4-chlorobenzylideneaminoxy propionic acid, ethyl ester 

Downstream Products

• 119881-37-7 (6R,7R)-3-Acetoxymethyl-7-{3-[1-(4-chloro-phenyl)-eth-(E)-ylideneaminooxy]-propionylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 119881-32-2 (6R,7R)-7-{3-[1-(4-Chloro-phenyl)-eth-(E)-ylideneaminooxy]-propionylamino}-3-methyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 134468-86-3 Sodium; (2S,3S)-3-{3-[1-(4-chloro-phenyl)-eth-(E)-ylideneaminooxy]-propionylamino}-2-methyl-4-oxo-azetidine-1-sulfonate 

Relevant articles and documents

Synthesis, antiinflammatory activity and platelet anti-aggregating activity of a new series of β-aminoxypropionic acids

A series of β-aminoxypropionic acids (AOPAs) had previously been designed and synthesised as analogues of antiinflammatory arylacetic acids (ArAAs) in which the Ar portion is substituted by the (methyleneaminoxy) methyl moiety (O = NOCH2, MAOMM

Oxime ether derivatives, a new class of nonsteroidal antiinflammatory compounds

A series of new 2-hydroxyethyl and carboxyalkyl ethers of aromatic oximes was found to possess pronounced antiinflammatory activity in the carrageenan-induced edema test in the rat. The activity was limited mainly to derivatives of p-haloacetophenone oxime and of p-halobenzaldehyde oxime. Nevertheless the hydroxyethyl and carboxyalkyl groups may be converted into many derivatives with maintenance of activity. Some structure-activity relationships are in contrast to those of the well-known antiinflammatory arylacetic acids. The activity is limited to the E stereoisomers. The hydrochloride of 2-(dimethylamino)ethyl (E)-[[(p-chloro-α- methylbenzylidene)-amino]oxy]acetate (36, INN name Cloximate) was cosen for clinical evaluation. The first results agree with the pharmacological prospects.